Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$2,004,496.00
Award Year:
2011
Program:
SBIR
Phase:
Phase II
Contract:
2R44AA016712-03A2
Award Id:
n/a
Agency Tracking Number:
R44AA016712
Solicitation Year:
2011
Solicitation Topic Code:
NIAAA
Solicitation Number:
PA09-095
Small Business Information
1790 Riverstone Drive, Delaware, OH, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
140535845
Principal Investigator:
ADACOWAN
(740) 815-9851
metallopharm@gmail.com
Business Contact:
JAMESCOWAN
(740) 815-9851
metallopharm@gmail.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): HCV is responsible for 60% of the cases of chronic hepatitis and 50% of cases of cirrhosis, end- stage liver disease, and liver cancer. An effective vaccine has proved elusive and the preferred therapy with pegylated interferon is effective in less than 50% of patients with genotype 1 and 75% of patients with genotypes 2 or 3. Clearly, new treatment alternatives are needed. Interest in HCV IRES RNA as a drug target is reflected by the increasing number of small and largepharma companies pursuing that goal. MetalloPharm has created a novel platform technology (metallodrugs) that has the potential to irreversibly destroy the HCV IRES RNA. The specific aims are directed toward selection of a lead and back-up drug candidatefor IND-enabling pre- clinical testing following validation of cellular mode of action against IRES RNA and uptake mechanisms; assessment of PK, toxicity and efficacy data; and exploration of methods to improve serum half life. PUBLIC HEALTH RELEVANCE: Millions of people worldwide are infected with HCV, including a significant portion of the US population. HCV is responsible for 60% of the cases of chronic hepatitis and 50% of cases of cirrhosis, end-stage liver disease, and liver cancer. An effective vaccine has proved elusive and current therapy is effective in less than 50% of patients. Clearly, new treatment alternatives are needed. MetalloPharm has created a novel class of therapeutics (metallodrugs) that function by destroying a key molecule inthe viral life cycle with the potential to halt the progression of, or completely eliminate the virus.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government